According to Archimedes Pharma, the Scottish Medicines Consortium has approved the company’s PecFent fentanyl pectin nasal spray for the treatment of breakthrough cancer pain for use in NHS Scotland. The product received marketing authorization in the European Union in September 2010 and is under review by the FDA for use in the US. Read the company’s press release.
